RECEIVED CENTRAL FAX CENTER APR 2 9 2009

PROPOSED AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A cobalamin derivative of formula (I):

wherein:

- (i) R^b is a spacer-chelator group optionally carrying a metal atom;
- (ii) R^c, R^d, and R^e are an antibiotic or antiproliferative therapeutic agent, or hydrogen; and R^R is an antibiotic or antiproliferative therapeutic agent connected through a linker Z, or hydrogen, wherein the linker Z is selected from the group consisting of phosphates, phosphonates, carboxylic esters, alkylenes of 1 to 10 carbon atoms, and combinations thereof;
 - (iii) with the proviso that at least one of the residues R^c, R^d, R^e and R^R are hydrogen;

Serial No. 10/583,760 Attorney Docket No. 2006_0804A April 21, 2009

- (iv) X is cyano, methyl, hydroxy, aquo or a 5'-deoxyadenosyl group; and
- (v) the central cobalt (Co) atom is optionally in the form of a radioactive isotope; and wherein the spacer-chelator group consists of an aliphatic chain of 2 to 4 carbon atoms carrying a chelator selected from the chelators of formulae (II) to (IX):

wherein carboxyl groups in formulae (Π) to (IX) may be present as esters; and said cobalamin derivative:

- (a) has no binding affinity or less than 20% binding affinity to transcobalamin II when compared to the binding affinity of non-modified cobalamin in a binding test, and
 - (b) retains activity as a vitamin B12 substitute.

Serial No. 10/583,760 Attorney Docket No. 2006_0804A April 21, 2009

- 20. (Currently amended) A method of diagnosis of a neoplastic disease in a mammal comprising
- (a) exposing the mammal suspected of being inflicted by a neoplastic disease or an infection to a period of a vitamin B12 free diet, and
- (b) subsequently applying a cobalamin derivative according to claim 1 carrying a diagnostic agent.